Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
10/23/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 201710/23/17
Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit09/25/17
Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development09/19/17
Investor Events More
There are currently no events scheduled.